Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Philippe Cassier

Showing results (21-30 of 54) with videos related to

Pageof 6
Sort By:
Translational Oncology|September 20, 2020
Therapeutic relevance of molecular screening program in patients with metastatic sarcoma: Analysis from the ProfiLER 01 trialPatrick Arnaud-Coffin, Mehdi Brahmi, Hélène Vanacker, et al.
Bulletin Du Cancer|January 31, 2008
[Imatinib and solid tumours]Samia Arifi, Hiba El Sayadi, Armelle Dufresne, et al.
European Journal of Cancer (Oxford, England : 1990)|June 12, 2012
Insulin-like growth factor type 1 receptor (IGF-1R) exclusive nuclear staining: a predictive biomarker for IGF-1R monoclonal antibody (Ab) therapy in sarcomasIrène Asmane, Emmanuel Watkin, Laurent Alberti, et al.
Oncology and Therapy|March 7, 2017
A Phase I, Dose-Escalation Trial of Pazopanib in Combination with Cisplatin in Patients with Advanced Solid Tumors: A UNICANCER StudyVéronique Diéras, Thomas Bachelot, Mario Campone, et al.
Medical Oncology (Northwood, London, England)|March 27, 2012
Serum creatine kinase increase in patients treated with tyrosine kinase inhibitors for solid tumorsAntoine Adenis, Olivier Bouché, François Bertucci, et al.
Future Oncology (London, England)|May 13, 2015
Multiparameter Phase I trials: a tool for model-based development of targeted agent combinations--example of EVESOR trialMevidette El-Madani, Emilie Hénin, Thibaud Lefort, et al.
BMJ Open|April 23, 2022
Reasons for acceptance and refusal of early palliative care in patients included in early-phase clinical trials in a regional comprehensive cancer centre in France: protocol for a qualitative studyGisele Chvetzoff, Magali Girodet, Johanna Despax, et al.
Genesis (New York, N.Y. : 2000)|March 20, 2020
Generation of an Fsp1 (fibroblast-specific protein 1)-Flpo transgenic mouse strainVictoire Cardot-Ruffino, Véronique Chauvet, Cassandre Caligaris, et al.
Scientific Reports|March 5, 2020
Generation of a conditional Flpo/FRT mouse model expressing constitutively active TGFβ in fibroblastsVictoire Cardot-Ruffino, Véronique Chauvet, Cassandre Caligaris, et al.
Cancer Medicine|March 30, 2024
Added value of whole-exome and RNA sequencing in advanced and refractory cancer patients with no molecular-based treatment recommendation based on a 90-gene panelArmelle Dufresne, Valéry Attignon, Anthony Ferrari, et al.
Pageof 6

Showing results (21-30 of 54) with videos related to

Sort By:
Pageof 6
Translational Oncology|September 20, 2020
Therapeutic relevance of molecular screening program in patients with metastatic sarcoma: Analysis from the ProfiLER 01 trialPatrick Arnaud-Coffin, Mehdi Brahmi, Hélène Vanacker, et al.
Bulletin Du Cancer|January 31, 2008
[Imatinib and solid tumours]Samia Arifi, Hiba El Sayadi, Armelle Dufresne, et al.
European Journal of Cancer (Oxford, England : 1990)|June 12, 2012
Insulin-like growth factor type 1 receptor (IGF-1R) exclusive nuclear staining: a predictive biomarker for IGF-1R monoclonal antibody (Ab) therapy in sarcomasIrène Asmane, Emmanuel Watkin, Laurent Alberti, et al.
Oncology and Therapy|March 7, 2017
A Phase I, Dose-Escalation Trial of Pazopanib in Combination with Cisplatin in Patients with Advanced Solid Tumors: A UNICANCER StudyVéronique Diéras, Thomas Bachelot, Mario Campone, et al.
Medical Oncology (Northwood, London, England)|March 27, 2012
Serum creatine kinase increase in patients treated with tyrosine kinase inhibitors for solid tumorsAntoine Adenis, Olivier Bouché, François Bertucci, et al.
Future Oncology (London, England)|May 13, 2015
Multiparameter Phase I trials: a tool for model-based development of targeted agent combinations--example of EVESOR trialMevidette El-Madani, Emilie Hénin, Thibaud Lefort, et al.
BMJ Open|April 23, 2022
Reasons for acceptance and refusal of early palliative care in patients included in early-phase clinical trials in a regional comprehensive cancer centre in France: protocol for a qualitative studyGisele Chvetzoff, Magali Girodet, Johanna Despax, et al.
Genesis (New York, N.Y. : 2000)|March 20, 2020
Generation of an Fsp1 (fibroblast-specific protein 1)-Flpo transgenic mouse strainVictoire Cardot-Ruffino, Véronique Chauvet, Cassandre Caligaris, et al.
Scientific Reports|March 5, 2020
Generation of a conditional Flpo/FRT mouse model expressing constitutively active TGFβ in fibroblastsVictoire Cardot-Ruffino, Véronique Chauvet, Cassandre Caligaris, et al.
Cancer Medicine|March 30, 2024
Added value of whole-exome and RNA sequencing in advanced and refractory cancer patients with no molecular-based treatment recommendation based on a 90-gene panelArmelle Dufresne, Valéry Attignon, Anthony Ferrari, et al.
Pageof 6